GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » EBIT

Hainan Poly Pharm Co (SZSE:300630) EBIT : ¥384 Mil (TTM As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co EBIT?

Hainan Poly Pharm Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was ¥145 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was ¥384 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Hainan Poly Pharm Co's annualized ROC % for the quarter that ended in Sep. 2023 was 12.22%. Hainan Poly Pharm Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 12.41%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Hainan Poly Pharm Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 4.95%.


Hainan Poly Pharm Co EBIT Historical Data

The historical data trend for Hainan Poly Pharm Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co EBIT Chart

Hainan Poly Pharm Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 210.33 337.62 461.66 523.25 479.07

Hainan Poly Pharm Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 197.01 -59.70 147.48 151.51 145.09

Competitive Comparison of Hainan Poly Pharm Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Hainan Poly Pharm Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hainan Poly Pharm Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hainan Poly Pharm Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Hainan Poly Pharm Co's EV-to-EBIT falls into.



Hainan Poly Pharm Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥384 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Poly Pharm Co  (SZSE:300630) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Hainan Poly Pharm Co's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=672.312 * ( 1 - -1.15% )/( (5445.526 + 5687.16)/ 2 )
=680.043588/5566.343
=12.22 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6299.681 - 462.236 - ( 391.919 - max(0, 938.447 - 2353.73+391.919))
=5445.526

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6687.316 - 552.579 - ( 447.577 - max(0, 1411.094 - 2722.404+447.577))
=5687.16

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Hainan Poly Pharm Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=580.368/( ( (3205.683 + max(1357.202, 0)) + (3228.011 + max(1559.176, 0)) )/ 2 )
=580.368/( ( 4562.885 + 4787.187 )/ 2 )
=580.368/4675.036
=12.41 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1099.965 + 447.524 + 384.018) - (462.236 + 0 + 112.069)
=1357.202

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1391.743 + 403.569 + 447.37) - (552.579 + 0 + 130.927)
=1559.176

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Hainan Poly Pharm Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=384.382/7762.511
=4.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hainan Poly Pharm Co EBIT Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Hainan Poly Pharm Co (SZSE:300630) Business Description

Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.
Executives
Fan De Zhu Independent director
Xie Hui Fang Supervisors
Pu Jian Executives
Xu Zhao Securities Affairs Representative
Shen Shi Hua Executives
Zhou Mao Directors, Directors, and Executives

Hainan Poly Pharm Co (SZSE:300630) Headlines

No Headlines